Skip to content

The Brief
Reports
The Pulse
- NeuroPulse
- OrphanPulse
Topics

Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront

Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront

Athithi Verma September 24, 2026

QuickDeal read/Deals Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront Athithi Verma· 24 September 2026· 2 min read· Synopulse InnoCare Pharma, listed…

J&J Is Using Two Tecvayli Trials to Own Myeloma's First Relapse Whether or Not Patients Had Darzalex

J&J Is Using Two Tecvayli Trials to Own Myeloma’s First Relapse Whether or Not Patients Had Darzalex

Henlius Licensed a US pH-Switch Platform for Two T-Cell Engager Targets Without Disclosing Any Payment

Henlius Licensed a US pH-Switch Platform for Two T-Cell Engager Targets Without Disclosing Any Payment

Roche Claims Best-in-Class Potential for Sefaxersen Without Disclosing How Much It Cut Proteinuria

Roche Claims Best-in-Class Potential for Sefaxersen Without Disclosing How Much It Cut Proteinuria

A Court Vacated the FDA's Biologic Classification of MiMedx's Wound Powder Because Similar Products Were Devices

A Court Vacated the FDA’s Biologic Classification of MiMedx’s Wound Powder Because Similar Products Were Devices

Plaintiffs Say CMS's Frailty Rule Raises Projected Medicaid Losses From 6.4 Million to 8.2 Million a Year

Plaintiffs Say CMS’ Frailty Rule Raises Projected Medicaid Losses From 6.4 Million to 8.2 Million a Year

Editor’s Pick

Rare Disease Produced Two First-Ever Approvals in Two Days, and Both of Them Are Neurology

Rare Disease Produced Two First-Ever Approvals in Two Days, and Both of Them Are Neurology

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

In Japan, Expanding a Label Is What Triggers the Price Cut

In Japan, Expanding a Label Is What Triggers the Price Cut

NeuroPulse

NeuroPulse Wk 38: Xenon Filed in Epilepsy and Paused in Psychiatry on the Same Day

NeuroPulse Wk 38: Xenon Filed in Epilepsy and Paused in Psychiatry on the Same Day

NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

OrphanPulse

OrphanPulse Wk 38: Two Untreatable Childhood Diseases Got First Therapies in 24 Hours

OrphanPulse Wk 38: Two Untreatable Childhood Diseases Got First Therapies in 24 Hours

OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

DealPulse Signal

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

Analysis

Radiopharmaceuticals: sixteen years of deal data on where the field goes next

Radiopharmaceuticals: sixteen years of deal data on where the field goes next

Behind the Headlines How the Leaders Really Performed

Behind the Headlines: How the Leaders Really Performed

Reshaping Pharma by 2027

7 Market Access Trends Reshaping Pharma by 2027

Coverage

ADCs Returned 0.46 in Relapsed Disease and 1.15 in the Front Line at WCLC

The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront

Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront

Athithi Verma September 24, 2026

J&J Is Using Two Tecvayli Trials to Own Myeloma's First Relapse Whether or Not Patients Had Darzalex

J&J Is Using Two Tecvayli Trials to Own Myeloma’s First Relapse Whether or Not Patients Had Darzalex

Athithi Verma September 24, 2026

Henlius Licensed a US pH-Switch Platform for Two T-Cell Engager Targets Without Disclosing Any Payment

Henlius Licensed a US pH-Switch Platform for Two T-Cell Engager Targets Without Disclosing Any Payment

Athithi Verma September 23, 2026

Roche Claims Best-in-Class Potential for Sefaxersen Without Disclosing How Much It Cut Proteinuria

Roche Claims Best-in-Class Potential for Sefaxersen Without Disclosing How Much It Cut Proteinuria

Athithi Verma September 23, 2026

A Court Vacated the FDA's Biologic Classification of MiMedx's Wound Powder Because Similar Products Were Devices

A Court Vacated the FDA’s Biologic Classification of MiMedx’s Wound Powder Because Similar Products Were Devices

Athithi Verma September 23, 2026

Plaintiffs Say CMS's Frailty Rule Raises Projected Medicaid Losses From 6.4 Million to 8.2 Million a Year

Plaintiffs Say CMS’ Frailty Rule Raises Projected Medicaid Losses From 6.4 Million to 8.2 Million a Year

Athithi Verma September 23, 2026

Explore Synopulse

NeuroPulse
Deals
Market Access
Industry Trends
Regulatory

About

About Synopulse
Contact Us
Announcements

© 2026 Synopulse • Built with GeneratePress